New study suggests Visbiome Vet may support gastrointestinal health in dogs undergoing chemotherapy treatment

A recent study published in Veterinary Record Open (Jugan, et. al) suggests that Visbiome® Vet probiotic may help mitigate occasional gastrointestinal concerns in dogs undergoing chemotherapy treatment for lymphoma.

A recent study published in Veterinary Record Open (Jugan, et. al) suggests that Visbiome® Vet probiotic may help mitigate occasional gastrointestinal concerns in dogs undergoing chemotherapy treatment for lymphoma.

The study was conducted at Kansas State University. Ten dogs with multicentric lymphoma were enrolled in this prospective, randomized, placebo-controlled, single-blinded study. Dogs either received an oral probiotic or oral placebo daily.

Forty percent of dogs had an unbalanced GI microbiome at baseline, and dysbiosis was common in dogs with multicentric lymphoma.

Results were promising. Not one dog receiving probiotics experienced occasional diarrhea, compared to 4 out of 5 dogs who received the placebo. Probiotics were well-tolerated, with no negative side effects reported. Such results suggest further exploration is required, both to examine the broader effects on the microbiome and to determine any clinical benefits.

"The impact of probiotics on this test group is remarkable and clearly warrants a larger study," said Marc Tewey, CEO of Visbiome Vet, manufacturer ExeGi Pharma. "Gut dysbiosis and occasional diarrhea in these trying situations are a concern for everyone involved, so we are grateful that Visbiome Vet was the focus of this important and promising research."

About Visbiome® Vet

Visbiome® Vet is a high potency probiotic for use in companion pets to help support normal inflammatory responses in the gastrointestinal tract (GI tract) and to help normalize gut health. The formulation in Visbiome Vet contains an eight-strain proprietary probiotic blend that has recently been studied in several canine GI concerns. Visbiome Vet is the identical formulation to Visbiome that has been the subject of over 70 human clinical trials.

About ExeGi Pharma

ExeGi Pharma LLC is a biotechnology company focused on developing and commercializing probiotic agents. ExeGi's team leverages scientific expertise in the field of microbiome science to deliver novel, clinically supported probiotic products for a variety of unmet health needs in humans and animals. ExeGi Pharma is dedicated to creating environmentally friendly products that balance business needs with green initiatives.

For more information on Visbiome Vet, visit


  • Please enter a comment

Name *
Email address *
Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

More news

Merck Animal Health Completes Acquisition of Elanco’s Aqua Business


Epidemiologic and tick exposure characteristics among people with reported Lyme disease – Minnesota, 2011–2019


Efficacy of Preemptive Analgesia with Amantadine for Controlling Postoperative Pain in Cats Undergoing Ovariohysterectomy


Major crossmatch compatibility of rabbit blood with rabbit, canine, and feline blood


Clinical Differences in Dogs with Enterococcal Bacteriuria Compared with Other Bacteriuria: A Retrospective, Case-Control Study




News of interest


Copyright © 2024 - All Rights Reserved
ISSN 2768-198X